SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Versicor (VERS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOEBT1 who wrote (38)3/17/2003 7:21:05 PM
From: Arthur Radley   of 83
 
Joe,
The primary endpoint is "okay" IMO....especially when you have a standard of 98% to beat. With that said, I do take pause over the recurrent number in which VERS admits that these are statistically significant results. In the CC, I think they handled this point as best they could... My take is that a large number of the trial patients in South Africa, Thailand and Argentina had no previous exposure to fluconazole and the built-up resistance wasn't as great as for the patients in the United States arm of the trial. Foresure, I think it common knowledge that here in the US we are quickly building up resistance by over prescribing antibiotics.

The after-hours trading is a little disconcerting in that it traded down by over a $1.00...but it was light trading. Tomorrow will be very interesting....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News